Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects

NCT01093508 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.

NCT NCT01093508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01093508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects
Lead sponsor
Arena Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2010
Completion date
July 31, 2010
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

narcolepsy with or without cataplexy